E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060573 |
E.1.2 | Term | Candidemia |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are to:
- Evaluate the safety and tolerability of CD101 Injection in the safety population.
- Evaluate overall success (mycological eradication and resolution of systemic signs and symptoms attributable to candidemia) of CD101 Injection in subjects with candidemia at Day 14 (±1 day) in the Microbiological Intent-to-treat (mITT) population. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to:
- Evaluate overall success (mycological eradication and resolution of systemic signs and symptoms attributable to candidemia) of CD101 Injection at Day 5 and Follow-up (FU, Days 45-52) in the mITT population.
- Evaluate mycological success (eradication) of CD101 Injection at Day 5, Day 14 (±1 day), and FU (Days 45-52) in the mITT population.
- Evaluate clinical cure as assessed by the Investigator for CD101 injection at Day 14 (±1 day) and FU (Days 45-52) in the mITT population.
- Evaluate the pharmacokinetics (PK) of CD101 Injection. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet ALL of the following inclusion criteria:
1. Males or females ≥18 years.
2. Established mycological diagnosis of candidemia from a blood sample taken ≤96 hours before randomization defined as:
a. ≥1 blood culture positive for yeast or Candida
OR
b. Positive test for Candida from a Sponsor-approved rapid IVD
3. Life expectancy >72 hours
4. Female subjects of child-bearing potential <2 years post-menopausal must agree to and comply with using one barrier method (e.g., female condom with spermicide) plus one other highly effective method of birth control (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, vasectomized partner), or sexual abstinence while participating in this study. Male subjects must agree to and comply with using one barrier method of birth control (e.g., male condom with spermicide) or sexual abstinence.
5. Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally authorized representative must provide informed consent on their behalf.
6. Presence of one or more systemic signs or symptoms attributable to candidemia (eg, fever, hypothermia, hypotension). |
|
E.4 | Principal exclusion criteria |
Subjects must NOT meet any of the following exclusion criteria:
1. Documented or suspected invasive candidiasis at any site including intra-abdominal infection, endocarditis, osteomyelitis, and meningitis
2. Neutropenia (absolute neutrophil count ≤500/μL) at screening or anticipated neutropenia during the study
3. Alanine aminotransferase or aspartate aminotransferase levels >10-fold the upper limit of normal
4. Severe hepatic impairment in subjects with a history of chronic cirrhosis (Child-Pugh score >9)
5. Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia for >48 hours (for example, >2 doses of a once daily antifungal agent or >4 doses of a twice daily antifungal agent) in the last 96 hours before randomization
a. Exception: Receipt of antifungal therapy to which any Candida spp. isolated in culture is not susceptible
6. Pregnant females
7. Lactating females who are nursing
8. Known hypersensitivity to CD101 Injection, caspofungin, any echinocandin, or to any of their excipients
9. Previous participation in this or any previous CD101 study.
10. Recent use of an investigational medicinal product within 28 days of the first dose of study drug or presence of an investigational device at the time of screening
11. The Principal Investigator considers that the subject should not participate in the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy end point is overall success at Day 14 (±1 day), as defined below:
- Mycological eradication defined as 2 negative blood cultures drawn ≥12 hours apart without intervening positive blood cultures and no change of antifungal therapy for the treatment of candidemia
AND
- Resolution of systemic signs and symptoms attributable to candidemia that were present at baseline
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy outcome measures include:
- Mycological eradication
- Clinical cure as assessed by the Investigator
Additional efficacy outcome measures include:
- All-cause 30-day mortality
- Time to first of 2 negative blood cultures drawn ≥12 hours apart
Blood samples will be obtained from subjects to evaluate the PK of CD101 Injection. Blood samples will be collected for all 3 treatment groups for the purpose of maintaining the blind, but only PK samples from the CD101 Injection groups will be analyzed by a central bioanalytical laboratory.
Safety will be assessed through the evaluation of AEs, vital signs (temperature, heart rate, blood pressure, and respiratory rate), ECGs, and clinical laboratory data (clinical chemistry panels, hematology evaluations, and urinalyses). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy assessments will be recorded on Day 5, Day 14 (±1 day), and FU (Days 45-52). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 45 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Greece |
Italy |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |